120 related articles for article (PubMed ID: 9037361)
1. Phase I/II trial of filgrastim (r-metHuG-CSF), CEOP chemotherapy and antiretroviral therapy in HIV-related non-Hodgkin's lymphoma.
Newell M; Goldstein D; Milliken S; Lewis C; Hoy J; Thomson B; Cooper D
Ann Oncol; 1996 Dec; 7(10):1029-36. PubMed ID: 9037361
[TBL] [Abstract][Full Text] [Related]
2. Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicin in patients with non-Hodgkin's lymphoma and advanced solid tumors.
Talbot SM; Westerman DA; Grigg AP; Toner GC; Wolf M; Bishop J; McKendrick J; Zalcberg J; Levi J; Fox RM; Green MD
Ann Oncol; 1999 Aug; 10(8):907-14. PubMed ID: 10509151
[TBL] [Abstract][Full Text] [Related]
3. Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor Therapy.
Fridrik MA; Greil R; Hausmaninger H; Krieger O; Oppitz P; Stöger M; Klocker J; Neubauer M; Helm W; Pont J; Fazeny B; Hudec M; Simonitsch I; Radaszkiewicz T
Ann Hematol; 1997 Oct; 75(4):135-40. PubMed ID: 9402845
[TBL] [Abstract][Full Text] [Related]
4. A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial.
Hertzberg M; Matthews JP; Stone JM; Dubosq MC; Grigg A; Ellis D; Benson W; Browett P; Horvath N; Januszewicz H; Abdi E; Green M; Bonaventura A; Marlton P; Cannell P; Wolf M;
Am J Hematol; 2014 May; 89(5):536-41. PubMed ID: 24481640
[TBL] [Abstract][Full Text] [Related]
5. A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (R-MeTHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL). The Central Lymphoma Group.
Smith GM; Child JA; Cullen MH; Bailey NP; Woodruffe CM; Fletcher J; Earl H; Barnard D
Hematol Oncol; 1996 Dec; 14(4):193-201. PubMed ID: 9267465
[TBL] [Abstract][Full Text] [Related]
6. Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma.
Sparano JA; Wiernik PH; Hu X; Sarta C; Schwartz EL; Soeiro R; Henry DH; Mason B; Ratech H; Dutcher JP
J Clin Oncol; 1996 Nov; 14(11):3026-35. PubMed ID: 8918501
[TBL] [Abstract][Full Text] [Related]
7. A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.
Sawka CA; Shepherd FA; Franssen E; Brandwein J; Dotten DA; Routy JP; Walker IR; St-Louis J; Taylor M; Arts K; Crump M; Foote M
Biotechnol Annu Rev; 2005; 11():381-9. PubMed ID: 16216784
[TBL] [Abstract][Full Text] [Related]
8. Treatment of aggressive non-Hodgkin's lymphoma with dose-intensified epirubicin in combination of cyclophosphamide, vincristine, and prednisone (CEOP-100): a phase II study.
Basaran M; Bavbek ES; Sakar B; Eralp Y; Alici S; Tas F; Yaman F; Dogan O O; Camlica H; Onat H
Am J Clin Oncol; 2001 Dec; 24(6):570-5. PubMed ID: 11801756
[TBL] [Abstract][Full Text] [Related]
9. A cooperative study of epirubicin with cyclophosphamide, vincristine and prednisone (CEOP) in non-Hodgkin's lymphoma.
Lambertenghi Deliliers G; Butti C; Baldini L; Ceriani A; Lombardi F; Luoni M; Montalbetti L; Pavia G; Pinotti G; Pogliani E
Haematologica; 1995; 80(4):318-24. PubMed ID: 7590500
[TBL] [Abstract][Full Text] [Related]
10. Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non-Hodgkin's lymphoma.
Tanosaki R; Okamoto S; Akatsuka N; Ishida A; Michikawa N; Masuda Y; Uchida H; Murata M; Kizaki M; Ikeda Y
Cancer; 1994 Oct; 74(7):1939-44. PubMed ID: 7521788
[TBL] [Abstract][Full Text] [Related]
11. Oral combination chemotherapy in conjunction with filgrastim (G-CSF) in the treatment of AIDS-related non-Hodgkin's lymphoma: evaluation of the role of G-CSF; quality-of-life analysis and long-term follow-up.
Remick SC; Sedransk N; Haase RF; Blanchard CG; Ramnes CR; Nazeer T; Mastrianni DM; Dezube BJ
Am J Hematol; 2001 Mar; 66(3):178-88. PubMed ID: 11279624
[TBL] [Abstract][Full Text] [Related]
12. Hodgkin's disease in 35 patients with HIV infection: an experience with epirubicin, bleomycin, vinblastine and prednisone chemotherapy in combination with antiretroviral therapy and primary use of G-CSF.
Errante D; Gabarre J; Ridolfo AL; Rossi G; Nosari AM; Gisselbrecht C; Kerneis Y; Mazzetti F; Vaccher E; Talamini R; Carbone A; Tirelli U
Ann Oncol; 1999 Feb; 10(2):189-95. PubMed ID: 10093688
[TBL] [Abstract][Full Text] [Related]
13. [Biweekly cyclophosphamide, epirubicin, vincristine and prednisolone (CEOP) chemotherapy for the elderly patients with aggressive non-Hodgkin's lymphoma. Tochigi Malignant Lymphoma Study Group for the Elderly Patients].
Izumi T; Muroi K; Hoshino Y; Komatsu N; Ohtsuki T; Yamada M; Tomizuka H; Hatake K; Furusawa S; Miura Y
Gan To Kagaku Ryoho; 1996 May; 23(6):797-800. PubMed ID: 8645033
[No Abstract] [Full Text] [Related]
14. Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP.
Economopoulos T; Dimopoulos MA; Mellou S; Pavlidis N; Samantas E; Nicolaides C; Tsatalas C; Papadopoulos A; Papageogriou E; Papasavvas P; Fountzilas G
Eur J Haematol; 2002 Mar; 68(3):135-43. PubMed ID: 12068793
[TBL] [Abstract][Full Text] [Related]
15. An EORTC pilot study of filgrastim (recombinant human granulocyte colony stimulating factor) as support to a high dose-intensive epiadriamycin-cyclophosphamide regimen in chemotherapy-naive patients with locally advanced or metastatic breast cancer.
Piccart MJ; Bruning P; Wildiers J; Awada A; Schornagel JH; Thomas J; Tomiak E; Bartholomeus S; Witteveen PO; Paridaens R
Ann Oncol; 1995 Sep; 6(7):673-7. PubMed ID: 8664188
[TBL] [Abstract][Full Text] [Related]
16. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.
Stoppa AM; Bouabdallah R; Chabannon C; Novakovitch G; Vey N; Camerlo J; Blaise D; Xerri L; Resbeut M; Di Stefano D; Bardou VJ; Gastaut JA; Maraninchi D
J Clin Oncol; 1997 May; 15(5):1722-9. PubMed ID: 9164178
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.
Ratner L; Lee J; Tang S; Redden D; Hamzeh F; Herndier B; Scadden D; Kaplan L; Ambinder R; Levine A; Harrington W; Grochow L; Flexner C; Tan B; Straus D;
J Clin Oncol; 2001 Apr; 19(8):2171-8. PubMed ID: 11304769
[TBL] [Abstract][Full Text] [Related]
18. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma.
Grigg A; Solal-Celigny P; Hoskin P; Taylor K; McMillan A; Forstpointner R; Bacon P; Renwick J; Hiddemann W;
Leuk Lymphoma; 2003 Sep; 44(9):1503-8. PubMed ID: 14565651
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505.
Itoh K; Ohtsu T; Fukuda H; Sasaki Y; Ogura M; Morishima Y; Chou T; Aikawa K; Uike N; Mizorogi F; Ohno T; Ikeda S; Sai T; Taniwaki M; Kawano F; Niimi M; Hotta T; Shimoyama M; Tobinai K;
Ann Oncol; 2002 Sep; 13(9):1347-55. PubMed ID: 12196359
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of standard and cyclophosphamide dose-escalated CHOP with granulocyte colony stimulating factor in elderly patients with non-Hodgkin's lymphoma.
Meyer RM; Gyger M; Langley R; Lespérance B; Caplan SN
Leuk Lymphoma; 1998 Aug; 30(5-6):591-600. PubMed ID: 9711921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
